|Rapid review complete
|For the treatment of chronic lymphocytic leukaemia (CLL)
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full HTA not recommended until further evidence available
|Following a resubmission of the rapid review a full pharmacoeconomic assessment is recommended on the basis of the proposed price, which is not comparable with current available therapies.
The HSE has approved reimbursement following confidential price negotiations – December 2018.